Tag: year

AB “Ignitis grupė” (hereinafter – the Group) has announced a Group CEO selection, as the second term of the current CEO, Darius Maikštėnas, ends on February 28, 2027. According to the Law on Companies of the Republic of Lithuania, the same person may be appointed as the CEO of a state-owned company for no more than two consecutive terms.

AB “Ignitis grupė” (hereinafter – the Group) has announced a Group CEO selection, as the second term of the current CEO, Darius Maikštėnas, ends on February 28, 2027. According to the Law on Companies of the Republic of Lithuania, the same person may be appointed as the CEO of a state-owned company for no more than two consecutive terms.

Announces Progress in Second U.S. Department of War Program of Record Through Tier-1 Defense Partner Supporting the U.S. Army’s LASSO Program

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ^®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada¹ and complements the adolescent label extension received in Europe in April 2025².

Revolutionary AI platform achieves 200,000 users milestone, showcasing unprecedented growth in the booming AI agent technology sector

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of shares of the Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Fund”) (tickers: RMJAX, RMHVX, RMHIX), between May 5, 2023 and June 12, 2025, inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline. The Fund is a mutual fund within defendant James Alpha Funds Trust’s series of mutual funds (which does business as Easterly Funds Trust).

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the “Western Asset US Core Bond Fund” mutual fund classes – Class I (ticker: “WATFX”), Class A (ticker: “WABAX”), Class C (ticker: “WABCX”), Class FI (ticker: “WAPIX”), Class IS (ticker: “WACSX”), and Class R (ticker: “WABRX”) – and the “Western Asset Core Plus Bond Fund” mutual fund classes – Class A (ticker: “WAPAX”), Class C (ticker: “WAPCX”), Class C1 (ticker: “LWCPX”), Class FI (ticker: “WACIX”), Class R (ticker: “WAPRX”), Class I (ticker: “WACPX”), Class IS (ticker: “WAPSX”) between January 1, 2021 and October 31, 2023, inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline.

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Fiserv, Inc. (NYSE: FI) between July 24, 2024 and July 22, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline.

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Flywire Corporation (NASDAQ: FLYW) between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important September 23, 2025 lead plaintiff deadline.

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of CTO Realty Growth, Inc. (NYSE: CTO, CTO-PA) between February 18, 2021 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 7, 2025.

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.